(NYSEMKT: CLDI) Calidi Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 63.61%.
Calidi Biotherapeutics's earnings in 2026 is -$23,455,000.On average, 3 Wall Street analysts forecast CLDI's earnings for 2026 to be -$14,676,615, with the lowest CLDI earnings forecast at -$14,100,858, and the highest CLDI earnings forecast at -$15,108,173. On average, 3 Wall Street analysts forecast CLDI's earnings for 2027 to be -$12,652,165, with the lowest CLDI earnings forecast at -$12,156,002, and the highest CLDI earnings forecast at -$13,024,287.
In 2028, CLDI is forecast to generate -$12,335,861 in earnings, with the lowest earnings forecast at -$11,852,101 and the highest earnings forecast at -$12,698,680.